BOLD vs CLRPF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLD is a Sell and CLRPF is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BOLD’s FA Score shows that 1 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).
- BOLD’s FA Score: 1 green, 4 red.
- CLRPF’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BOLD’s TA Score shows that 4 TA indicator(s) are bullish.
- BOLD’s TA Score: 4 bullish, 6 bearish.
Price Growth
BOLD (@Biotechnology) experienced а -14.00% price change this week, while CLRPF (@Biotechnology) price change was -2.95% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.
Reported Earning Dates
BOLD is expected to report earnings on Nov 08, 2024.
Industries' Descriptions
@Biotechnology (-8.58% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BOLD | CLRPF | BOLD / CLRPF | |
| Capitalization | 67.1M | 1.48B | 5% |
| EBITDA | -64.01M | N/A | - |
| Gain YTD | N/A | 257.364 | - |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | N/A | - |
| Total Cash | 179M | N/A | - |
| Total Debt | 837K | N/A | - |
| BOLD | |
|---|---|
| RSI ODDS (%) | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 71% |
| Momentum ODDS (%) | 3 days ago 78% |
| MACD ODDS (%) | 3 days ago 67% |
| TrendWeek ODDS (%) | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 90% |
| Advances ODDS (%) | 6 days ago 74% |
| Declines ODDS (%) | 3 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 90% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| HDDVX | 15.89 | -0.08 | -0.50% |
| Janus Henderson Responsible Intl Div D | |||
| WFGGX | 27.80 | -0.34 | -1.21% |
| First Trust WCM Focused Global Gr Inv | |||
| SUSLX | 14.91 | -0.22 | -1.45% |
| Lazard US Sustainable Equity Open | |||
| TILGX | 29.39 | -0.71 | -2.36% |
| Nuveen Large Cap Growth R6 | |||
| DRGTX | 87.43 | -2.21 | -2.47% |
| Virtus Zevenbergen Technology Inst | |||
BOLD and
Correlation & Price change
A.I.dvisor tells us that BOLD and ETXPF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOLD and ETXPF's prices will move in lockstep.
| Ticker / NAME | Correlation To BOLD | 1D Price Change % | ||
|---|---|---|---|---|
| BOLD | 100% | -7.10% | ||
| ETXPF - BOLD | 32% Poorly correlated | N/A | ||
| KOD - BOLD | 32% Poorly correlated | +4.34% | ||
| TNXP - BOLD | 32% Poorly correlated | -6.36% | ||
| GRI - BOLD | 25% Poorly correlated | -19.57% | ||
| AKBA - BOLD | 25% Poorly correlated | -3.76% | ||
More | ||||
CLRPF and
Correlation & Price change
A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.
| Ticker / NAME | Correlation To CLRPF | 1D Price Change % | ||
|---|---|---|---|---|
| CLRPF | 100% | -2.95% | ||
| SBHMY - CLRPF | 24% Poorly correlated | N/A | ||
| BOLD - CLRPF | 23% Poorly correlated | -7.10% | ||
| HEPA - CLRPF | 22% Poorly correlated | +2.26% | ||
| AKBA - CLRPF | 21% Poorly correlated | -3.76% | ||
| DOSEF - CLRPF | 12% Poorly correlated | N/A | ||
More | ||||